Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Receivables - Other: 2024-2025

  • Avidity Biosciences' Receivables - Other was N/A to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year change of. This contributed to the annual value of $9.4 million for FY2024, which is N/A change from last year.
  • Avidity Biosciences' Receivables - Other amounted to $15.0 million in Q3 2025, which was up 76.08% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Receivables - Other peaked at $15.0 million during Q3 2025, and registered a low of $8.5 million during Q2 2025.
  • Over the past 2 years, Avidity Biosciences' median Receivables - Other value was $9.4 million (recorded in 2024), while the average stood at $11.0 million.